Imunon, Inc. (IMNN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Imunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 EXHIBIT 10.1 IMUNON, INC. THE 2018 STOCK INCENTIVE PLAN AS AMENDED AS OF JUNE 16, 2026 I. INTRODUCTION 1.1 Purposes . The purposes of the IMUNON, INC. 2018 Stock Incentive Plan (this “ Plan ”) are (i) to align the interests of the Company’s stockholde
How this was made
The 30-second read
Why it matters
This disclosure primarily updates governance and compensatory arrangements, which can influence expectations for future equity grants and corporate control dynamics.
Market read
For IMUNON, the actionable takeaway is potential changes in leadership and equity compensation structure, but the provided excerpt lacks the specific award/individual details needed for a high-conviction trade.
What to watch
Traders should verify the full 8-K exhibits for the specific named officers/directors and any quantitative award terms; those details would better determine dilution and sentiment impact.
Background
The SEC 8-K references Item 5.02/5.07 and includes Exhibit 10.1 describing the amended IMUNON 2018 Stock Incentive Plan as of June 16, 2026.
Ticker impact
IMUNON filed an 8-K covering director/officer departures and elections plus compensatory arrangements under its amended 2018 stock incentive plan.
Likely modest, sentiment-driven move; direction uncertain without specific award sizes or named officer changes in the provided excerpt.
The excerpt is largely plan boilerplate and does not include the specific departing/elected individuals or the exact compensation amounts, limiting conviction on magnitude and direction.
Market effects
Limited sector read-through; this is company-specific governance/equity-plan administration rather than an industry catalyst.
No clear regional spillover indicated.
No global linkage indicated.
Counterpoint
Equity-plan amendments and board/officer reshuffles can be routine and non-dilutive in practice if grants are modest or offset by forfeitures.
Key entities
- companyImunon, Inc.
Subject of the SEC 8-K; filed director/officer change and compensatory arrangement disclosures plus an amended stock incentive plan exhibit.
